NFKB1 and ovarian cancer: Inhibition of p62 by RNAi significantly reduced the translocation of p50/p65 into the nucleus and inhibited the transcriptional activity of NF-κB, which suggests that p62 may control cisplatin resistance in ovarian cancer cells by regulating NF-κB signaling [31].